<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02410603</url>
  </required_header>
  <id_info>
    <org_study_id>15-000373</org_study_id>
    <nct_id>NCT02410603</nct_id>
  </id_info>
  <brief_title>Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer</brief_title>
  <official_title>Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford BioDynamics</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the detection of circulating tumor DNA, soluble
      immune markers, and the evaluation of peripheral blood mononuclear cells (PBMC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our plan is to collect blood from patients with advanced stage lung cancer who are scheduled
      to undergo systemic therapy. In this study we will utilize a novel technology for circulating
      tumor DNA detection in order to evaluate their presence in patients with lung cancer by
      comparing blood samples at six time points. We will obtain baseline blood and then collect
      blood at five time points during the course of the patient's chemotherapy treatments and at
      the end of treatment. These same blood collections will be used for the detection of soluble
      immune markers and evaluation of PBMCs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary end point is the number and type of mutations detectable in the circulating tumor DNA blood samples.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Lung Neoplasms</condition>
  <condition>Cancer of Lung</condition>
  <condition>Cancer of the Lung</condition>
  <condition>Neoplasms, Lung</condition>
  <condition>Neoplasms, Pulmonary</condition>
  <condition>Pulmonary Cancer</condition>
  <condition>Pulmonary Neoplasms</condition>
  <condition>Carcinoma, Non-small-cell Lung</condition>
  <condition>Adenocarcinoma</condition>
  <condition>Squamous Cell Carcinoma</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced stage cancer in the thorax who are scheduled to undergo systemic
        therapy at the Mayo Clinic in Rochester, MN.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced (non-resectable) malignancy in the thorax

          -  Age &gt;18 years old

          -  Willing and able to provide consent

          -  No prior history of neoadjuvant therapy

        Exclusion Criteria:

          -  Age &lt;18 years old

          -  Unable to provide consent

          -  Patients with hemoglobin less than 10 g/dL (to minimize the impact of potential
             iatrogenic anemia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Mansfield, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karlyn Pierson, RN</last_name>
    <phone>507-538-1960</phone>
    <email>pierson.karlyn@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bettie Lechtenberg, MBA</last_name>
    <phone>507-266-4819</phone>
    <email>lechtenberg.bettie@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karlyn Pierson, RN</last_name>
      <phone>507-538-1960</phone>
      <email>pierson.karlyn@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron Mansfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Aaron S. Mansfield, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

